

Physician Login

Healthcare Professionals

Patients and Caregivers

Press Room

 Contact Us

Webcasts











Videos and webcasts available on demand

Guiding N1 treatment decisions after RxPONDER

Prof. Catherine Kelly from the Trinity St James Cancer Institute in Dublin presents the RxPONDER results.

Initial RxPONDER results in clinical practice: What will change?

Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial ...

Clinical practice revisited: Improving chemotherapy treatment decisions in early-stage breast cancer

Prof. Hartkopf from the University of Tuebingen talks about the evidence from his clinical practice and which parameters guide treatment decisions in ...

The Oncotype DX Breast Recurrence Score assay in clinical practice

Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast ...

Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy

Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment ...

Challenging Node-positive Case Studies Webinar

Drs. Jeremy Force and Christy Russell discuss how physicians can use the Breast Recurrence Score test and the recently presented data from the RxPONDER trial to inform chemotherapy decisions.

WATCH VIDEO

Applying RxPONDER To Clinical Practice

Drs. Tari King and Kathy Miller discuss lymph node-positive breast cancer cases with Dr. Christy Russell.

WATCH VIDEO

Podcast Available On-Demand

Drs. Alison Laws, Philip Poorvu, and Sara Hurvitz discuss the utility of the Breast Recurrence Score^® test for node-positive, HR+, HER2- breast cancer patients.

LISTEN TO PODCAST

Contact Us

Get in Touch



Home

HIPAA Notice

Do Not Sell My Information

Do Not Sell My Information

Terms & Conditions

Worldwide Websites

In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.

Making cancer care smarter.™



Webcasts

Videos and webcasts available on demand

Challenging Node-positive Case Studies Webinar

Applying RxPONDER To Clinical Practice

Podcast Available On-Demand

Contact Us

Oncotype DX Breast Recurrence Score

Patients And Caregivers

Resources